-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3056 First Line Therapy Evaluation Using Propensity Score Approach in Newly Diagnosed Advanced Classical Hodgkin Lymphoma Patients from Prospective Real-World Realysa Cohort and Phase 3 AHL2011 Trial

Program: Oral and Poster Abstracts
Session: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Research, clinical trials, Hodgkin lymphoma, adult, Lymphomas, Combination therapy, Clinical Research, Diseases, Therapies, real-world evidence, clinical procedures, Lymphoid Malignancies, Technology and Procedures, Human
Sunday, December 10, 2023, 6:00 PM-8:00 PM

Cedric Rossi, MD1,2, Amira Marouf, MD3*, Benedicte Deau Fischer, MD4*, Fanny Cherblanc, PhD5*, Emeline Cugnod5*, Loic Chartier5*, Luc Matthieu Fornecker, MD, PhD6*, Marc Andre, MD, PhD7*, Rene-Olivier Casasnovas, MD8* and Herve Ghesquieres, MD, PhD9*

1Stanford University, Stanford, CA
2CHU Dijon, DIJON, France
3CHU Cochin, Paris, France
4Hopital d'Antony Ramsay, Antony, France
5Lymphoma Academic Research Organisation, Lyon, France
6Institut de cancérologie Strasbourg Europe, Strasbourg, France
7CHU UCL Namur, Yvoir, Belgium
8CHU Dijon, Dijon, France
9Hopital Lyon Sud, Pierre Benite, France

Background: AHL2011, a randomized phase III trial demonstrated that PET-CT after two cycles of BEACOPPescalated chemotherapy safely guided treatment of patients aged 16–60 years with newly diagnosed advanced classical Hodgkin lymphoma (cHL) and allowed the use of ABVD in early responders with reduced toxicities and no impaired disease control. REALYSA study, a real-life multicentric cohort set up in France since 2018, included 6000 newly diagnosed lymphoma patients with over 1000 cHL patients. In the present study, we investigated whether real-world data could reproduce results issued from a randomized phase III clinical trial using the propensity score approach.

Methods: After stringent propensity score matching (PSM) on 10 baseline parameters (gender, age, Ann Arbor stage, ECOG Performance Status, number of extranodal sites involved, B symptoms, albumin, hemoglobin, white blood cell count and lymphocytes), we performed a PSM testing ratios 1:1 (one patient from AHL2011 trial and one patient from REALYSA cohort). All patients from AHL2011 and REALYSA included in this study had PET-CT monitoring after two cycles of BEACOPPescalated. This approach allowed us to build well-balanced pairs as demonstrated by the absolute values of the standardize mean differences (SMDs) below 0.1 for all matching covariates except for ECOG (SMD=0.15). We also used the Inverse Probability of Treatment Weighting (IPTW, IPTW stabilized) to compare the experimental arm of the AHL2011 trial with a synthetic control arm established with real-world data from REALYSA cHL patients who respected the main inclusion criteria of AHL2011 trial and were treated following this PET-guided approach. The median follow-up was censored in the AHL2011 data in order to be comparable to the median follow-up observed in the REALYSA cohort.

Results: Among the 823 patients of AHL2011 and 942 patients of REALYSA with newly diagnosed cHL, 390 and 100 patients respectively were eligible for propensity score calculation, corresponding to AHL2011 TEP-guided therapy, aged between 16 and 60 years, no missing data for the covariates included in the PSM and at least 12 months of follow-up in the REALYSA study. After 1:1 PSM (n=98 AHL2011 and n=98 REALYSA), the overall response rate at the end of induction was 91.8% vs 89.8% (p=0.81) for patients included in AHL2011 and REALYSA, respectively. The proportion of patients with positive PET-CT after 2 cycles was similar in AHL2011 (13%) and REALYSA (14%). After a median follow-up of 13 months, the 1-year progression free survival rates were 93.8% and 87.8% (HR=0.87; 95%CI 0.4-2.0; P=0.74) in AHL2011 and REALYSA, respectively (Figure 1A). Using IPTW model including covariates from the PSM, similar PFS were obtained between experimental arm of AHL2011 and patients included in REALYSA (Figure 1B). IPTW stabilized and other IPTW models also showed similar results for PFS.

Conclusions: In this study, we demonstrated using a propensity score approach that patients with newly diagnosed advanced cHL treated according to the AHL2011 PET-guided frontline approach in routine care and included in REALYSA cohort reached similar outcomes as patients included in prospective phase III clinical trial. Beyond the relevant validation of the AHL2011 trial results in real-life, which will need longer follow up, these data could be used to design composite control arm for future clinical trials.

Disclosures: Casasnovas: ADC therapeutics: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Research Funding; MSD: Consultancy, Honoraria; Kite/Gilead: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria; Astra Zeneca: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Beigene: Consultancy, Honoraria; Roche: Consultancy, Honoraria, Research Funding. Ghesquieres: Gilead, Roche, Bristol Myers Squibb, AbbVie, Novartis: Honoraria; Gilead, Roche: Consultancy.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH